Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.25 – $4.15
71% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.4M | $20.4M | $9.3M | $9.3M | $189.6M | $7.0M | $5.0M | $0 |
| Cost of revenue | $15.6M | $43.5M | $56.1M | $55.0M | $49.9M | $47.8M | $47.5M | $2.1M |
| Gross profit | −$5.2M | −$23.1M | −$46.7M | −$45.6M | $139.7M | −$40.8M | −$42.5M | −$2.1M |
| Gross margin | -50.7% | -113.4% | -500.1% | -489.1% | 73.7% | -579.8% | -855.8% | — |
| R&D | $38.2M | $43.5M | $56.1M | $55.7M | $50.7M | $48.8M | $48.6M | $40.2M |
| Operating income | −$37.4M | −$36.7M | −$58.3M | −$63.4M | $116.6M | −$61.1M | −$61.2M | −$55.5M |
| EBITDA | −$36.5M | −$33.7M | −$59.6M | −$60.7M | $120.8M | −$59.5M | −$51.6M | −$53.3M |
| Net income | −$37.0M | −$36.3M | −$62.8M | −$63.8M | $117.9M | −$62.0M | −$54.0M | −$61.7M |
| Net margin | -357.7% | -178.0% | -671.7% | -683.7% | 62.2% | -880.7% | -1087.4% | — |
| EPS (diluted) | -1.75 | -1.69 | -2.51 | -2.06 | 3.54 | -1.89 | -1.63 | -1.65 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-1.42 | $-1.42–$-1.42 | 1 |
| 2027 | $60M | $-1.30 | $-1.30–$-1.30 | 1 |
| 2028 | $1M | $-1.50 | $-1.50–$-1.50 | 1 |
| 2029 | $33M | $-1.45 | $-1.45–$-1.45 | 1 |
Forward consensus · source: Financial Modeling Prep
MOLECULAR PARTNERS AG ORD
No one on the platform currently holds MLLCF.
No tracked institution reports a position in MLLCF as of their last filing.
No one on the platform has traded MLLCF yet.
| +0.00% |
| $66M |
| — |
| IPHYFInnate Pharma S.A. | $1.65 | +0.00% | $155M | — |
| JWCTFJW (Cayman) Therapeutics Co. Ltd | $0.24 | +0.00% | $99M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 53.5× sales vs its 26.3× historical median P/S.
Fair value ≈ $1.77 · price $3.60 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$MLLCF Q4 '25 Earnings Results & Recap For the full year 2026, Molecular Partners expects total operating expenses of CHF45M at constant exchange rates, including approximately CHF6M in non-cash effective costs.
View on StockTwits ↗Molecular Partners Sees Short Interest Decrease from 113,400 shares to 71,200 shares. $MLLCF https://www.marketbeat.com/stocks/OTCMKTS/MLLC
View on StockTwits ↗Molecular Partners Sees Short Interest Decrease from 113,400 shares to 71,200 shares. $MLLCF https://www.marketbeat.com/stocks/OTCMKTS/MLLC
View on StockTwits ↗Molecular Partners's PT cut by Credit Suisse Group AG to CHF 6. https://www.marketbeat.com/r/1794611 $MLLCF
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.